Figure 2: The immunogenicity and safety evaluation of PP-3copy-Aβ1-6-loop123 in WT C57BL/6 mice. | Scientific Reports

Figure 2: The immunogenicity and safety evaluation of PP-3copy-Aβ1-6-loop123 in WT C57BL/6 mice.

From: Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer’s disease

Figure 2

(a) Dose-response study of PP-3copy-Aβ1-6-loop123 in C57BL/6 mice. Aβ42 antibody levels in the serum of mice after four immunizations with PBS, CpG, PP-3copy-Aβ1-6-loop123 in different dosage or Aβ42 were examined by ELISA. Absorbance values greater than twofold over the background were considered positive and are marked with *. (b) Detection of antibody levels against P particle in different mice groups after four immunizations with PP-3copy-Aβ1-6-loop123. Absorbance values greater than twofold over the background were considered positive and are marked with *. (c) Activation of Aβ42-specific T-cells from each group were assessed by Elispot assay (T-cell activation). Isolated spleen cells from each group were stimulated with Aβ42 peptide and IFN-γ-secreting T-cell spots were quantified. Statistically significant difference were observed between PBS and Aβ42 peptide immunized mice (P = 0.0375), as well as 25 μg PP-3copy-Aβ1-6-loop123 + CpG and Aβ42 peptide immunized groups (P = 0.0472). *p < 0.05, NS = non-significant. (d) The determination of the stimulation of P particle-specific T-cells of each group by Elispot assay (T-cell activation). Isolated spleen cells from each group were stimulated with P particle protein and IFN-γ-secreting T-cell spots were quantified. Statistically significant differences were observed between CpG and 25 μg PP-3copy-Aβ1-6-loop123 + CpG immunized groups (P = 0.0004). ***p < 0.0001, NS = non-significant. All the results were expressed as mean values ± SEM. ANOVA test was used to analyze the statistical significance of the data.

Back to article page